Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. -) - Phio ...
Phoenix-based Banner Health receives $74.5 million grant to study Alzheimer's
The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing ...